Esperion Therapeutics (ESPR) - NASDAQ
  • Fri, Jul. 8, 12:25 PM
    • Anthera Pharmaceuticals (NASDAQ:ANTH) initiated with Buy rating and $10 (180% upside) price target by H.C. Wainwright.
    • Ultragenyx Pharmaceutical (NASDAQ:RARE) initiated with Overweight rating and $70 (31% upside) price target by Piper Jaffray.
    • Eiger Biopharmaceuticals (NASDAQ:EIGR) initiated with Outperform rating and $34 (85% upside) price target by Oppenheimer.
    • Intercept Pharmaceuticals (NASDAQ:ICPT) initiated with Sell rating and $58 (61% downside risk) price target by Cantor Fitzgerald.
    • Juno Therapeutics (NASDAQ:JUNO) initiated with Equal Weight rating and $48 (73% upside) price target by Barclays.
    • Kite Pharma (NASDAQ:KITE) initiated with Equal Weight rating and $58 (21% upside) price target by Barclays.
    • Endologix (NASDAQ:ELGX) upgraded to Outperform from Market Perform by BMO Capital. Price target raised to $16 (14% upside) from $11.50.
    • Achillion Pharmaceuticals (NASDAQ:ACHN) upgraded to Outperform from Market Perform with a $13 (42% upside) price target by JMP Securities.
    • Humana (NYSE:HUM) downgraded to Neutral from Overweight by JPMorgan. Price target lowered to $150 (8% downside risk) from $196.
    • Ilumina (NASDAQ:ILMN) downgraded to Underweight from Equal Weight by Morgan Stanley. Price target lowered to $110 (22% downside risk) from $130.
    • T2 Biosystems (NASDAQ:TTOO) downgraded to Sell from Buy by BTIG Research. Price target lowered to $4 (26% downside risk) from $12.
    • Juno Therapeutics (JUNO) downgraded to Neutral from Overweight by JPMorgan. Price target lowered to $39 (40% upside) from $63.
    • Depomed (NASDAQ:DEPO) downgraded to Neutral from Buy with $20 (6% upside) price target by UBS.
    • Esperion Therapeutics (NASDAQ:ESPR) downgraded to Hold from Buy by WallachBeth.
    | Fri, Jul. 8, 12:25 PM | 4 Comments
  • Fri, Jul. 1, 10:28 AM
    • GlaxoSmithKline (NYSE:GSK) upgraded to Buy from Neutral by Citigroup. Price target is 1800p (14% upside).
    • Alexion Pharmaceuticals (NASDAQ:ALXN) upgraded to Buy from Neutral by Citigroup. Price target is $154 (29% upside).
    • IPG Photonics (NASDAQ:IPGP) upgraded to Buy from Hold by Canaccord Genuity. Price target raised to $90 (13% upside) from $85.
    • Centene (NYSE:CNC) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target raised to $86 (21% upside) from $84.
    • Pacira Pharmaceuticals (NASDAQ:PCRX) downgraded to Hold from Buy by Brean Capital.
    • TESARO (NASDAQ:TSRO) downgraded to Hold from Buy by Jefferies.
    • Esperion Therapeutics (NASDAQ:ESPR) downgraded to Equal Weight from Overweight with a $13 (26% upside) price target (from $28) by Barclays. Downgraded to Neutral from Overweight with a $15 (46% upside) price target (from $50) by JPMorgan. Downgraded to Underperform from Neutral with a $10 (0% upside) price target (from $23) by Credit Suisse.
    • HeartWare International (NASDAQ:HTWR) downgraded to Market Perform from Outperform by Wells Fargo. Downgraded to Neutral from Buy with a $58 (0% upside) price target (from $60) by SunTrust Robinson Humphrey.
    • Regulus Therapeutics (NASDAQ:RGLS) downgraded to Market Perform from Outperform by BMO Capital. Price target lowered to $4 (30% upside) from $16.
    • HealthSouth (NYSE:HLS) downgraded to Underweight from Equal Weight by Barclays. Price target lowered to $42 (8% upside) from $45.
    • SciQuest (NASDAQ:SQI) downgraded to Market Perform from Outperform by Raymond James.
    • Quest Diagnostics (NYSE:DGX) downgraded to from Neutral to Sell by Jyske Bank.
    | Fri, Jul. 1, 10:28 AM | 5 Comments
  • Wed, Jun. 29, 12:46 PM
    | Wed, Jun. 29, 12:46 PM
  • Wed, Jun. 29, 11:10 AM
    | Wed, Jun. 29, 11:10 AM
  • Wed, Jun. 29, 9:16 AM
    | Wed, Jun. 29, 9:16 AM | 3 Comments
  • Tue, Jun. 28, 5:37 PM
    • Top gainers, as of 5.25 p.m.: FUEL +3.1%. FSM +3.5%. HMY +2.1%. GFI +1.9%. INO +1.7%.
    • Top losers, as of 5.25p.m.: ESPR -24.0%. ANTH -7.2%. NKE -6.6%. HTCH -6.5%.
    | Tue, Jun. 28, 5:37 PM | 2 Comments
  • Tue, Jun. 28, 5:07 PM
    • Nano cap Esperion Therapeutics (NASDAQ:ESPR) had a ugly day today despite the market's up move. Shares slumped almost 20% on more than a 35% spike in volume as informed investors ran for the exits ahead of the company's press announcement released at 4:05 pm which updated investors on the clinical development and regulatory path for lead product candidate bempedoic acid, its candidate for lowering "bad" cholesterol in patients intolerant of statins.
    • The good news is that a global pivotal Phase 3 trial to assess safety and efficacy should commence in Q4 as will a cardiovascular outcomes study. Esperion says the study timelines will support a European marketing application in 2019 for patients with elevated LDL-C, including those intolerant of statins and one in 2022 for CV disease risk reduction in statin-intolerant patients.
    • The bad news is the FDA's refusal to clarify a regulatory pathway for the LDL-C indication citing potential changes in their view of LDL-C lowering as a surrogate endpoint and the possibility of a shift in the future standard-of-care for statin-intolerant patients with elevated LDL-C. According to the company, if, indeed, lowering LDL-C is no longer a surrogate endpoint for approval, it will still submit a New Drug Application (NDA) for a CV disease risk reduction claim by 2022, which means potential approval is at least six years away.
    • Bempedoic acid is a small molecule that lowers cholesterol without the side effects associated with statins. Once in the liver, it converts into a derivative coenzyme which directly inhibits an enzyme called ATP citrate lyase (ACL), which plays a key role in cholesterol and fatty acid synthesis.
    • Update: Shares are down 24% after hours on robust volume.
    | Tue, Jun. 28, 5:07 PM | 12 Comments
  • Wed, May 4, 8:12 AM
    • Esperion Therapeutics (NASDAQ:ESPR): Q1 EPS of -$0.65 beats by $0.09.
    • Cash and equivalents of $37.2M.
    • Press Release
    | Wed, May 4, 8:12 AM | 7 Comments
  • Wed, Jan. 13, 9:44 AM
    • Esperion Therapeutics (NASDAQ:ESPR) commences a global Phase 3 long-term safety and tolerability study, called ETC-1002-040, assessing bempedoic acid (ETC-1002) in patients with hyperlipidemia (excess fat in the blood) whose LDL-C (bad cholesterol) is not adequately controlled with low-to-moderate dose statins. Top-line results should be available in Q4 2017.
    • The randomized, multicenter, double-blind, placebo-controlled study will evaluate a daily dose of 180 mg of bempedoic acid versus placebo in 900 patients at high cardiovascular risk. The primary endpoint is the safety and tolerability over 52 weeks. Secondary endpoints will assess the effects of bempedoic acid on various lipid and cardiometabolic measurements.
    • The study marks the launch of the company's Phase 3 development program of bempedoic acid, called CLEAR, focused on statin-intolerant patients with uncontrolled LDL-C levels. Management will provide more details on CLEAR in Q2.
    • Bempedoic acid is a small molecule that lowers cholesterol without the side effects associated with statins. Once in the liver, it converts into a derivative coenzyme which directly inhibits an enzyme called ATP citrate lyase (ACL), which plays a key role in cholesterol and fatty acid synthesis.
    | Wed, Jan. 13, 9:44 AM
  • Tue, Jan. 12, 4:37 PM
    • Esperion Therapeutics (NASDAQ:ESPR) commences a Phase 2 clinical trial assessing lead product candidate, bad cholesterol-lowering bempedoic acid (ETC-1002), in patients with high cholesterol being treated with atorvastatin 80 mg (Pfizer's LIPITOR), the most commonly prescribed statin. Top-line results should be available by mid-year.
    • The 60-subject, randomized, double-blind, parallel group study will assess once-daily 180 mg of bempedoic acid or placebo in patients on stable atorvastatin therapy of 80 mg per day. The primary endpoint is the change in LDL cholesterol versus placebo against a background of atorvastatin.
    • Bempedoic acid is a small molecule that lowers cholesterol without the side effects associated with statins. Once in the liver, it converts into a derivative coenzyme which directly inhibits an enzyme called ATP citrate lyase (ACL), which plays a key role in cholesterol and fatty acid synthesis.
    | Tue, Jan. 12, 4:37 PM | 4 Comments
  • Oct. 12, 2015, 9:13 AM
    | Oct. 12, 2015, 9:13 AM | 6 Comments
  • Oct. 12, 2015, 8:38 AM
    • Eli Lilly (NYSE:LLY) is down 10% premarket on robust volume in response to its announcement that it has terminated the development of evacetrapib for the treatment of high-risk atherosclerotic cardiovascular disease due to lack of efficacy. Its decision was based on a review by the independent data monitoring committee.
    • The move will result in a Q4 charge to R&D expense of up to $90M ($0.05 per share after tax). The company will incorporate the change in its 2015 guidance that it will provide during its earnings call on October 22.
    • SVP and President of Lilly Bio-Medicines David Ricks says, "We're obviously disappointed in this outcome, as we hoped the evacetrapib would offer an advance in treatment for people with high-risk cardiovascular disease. We'll be working with investigators to appropriately conclude these trials. We remain confident in our pipeline as we prepare for launches in other therapeutics areas with significant unmet needs."
    • Related tickers and status premarket: (NASDAQ:REGN+4%; (NASDAQ:AMGN+3%; (NASDAQ:ESPR+14%; (NYSE:SNY+1%.
    | Oct. 12, 2015, 8:38 AM | 7 Comments
  • Sep. 30, 2015, 9:13 AM
    | Sep. 30, 2015, 9:13 AM
  • Sep. 29, 2015, 12:41 PM
    | Sep. 29, 2015, 12:41 PM
  • Sep. 29, 2015, 9:14 AM
    | Sep. 29, 2015, 9:14 AM
  • Sep. 29, 2015, 9:08 AM
    • Esperion Therapeutics (NASDAQ:ESPR) is down 15% premarket on increased volume in response to the news of its Phase 3 development plan for its lead product candidate, bad cholesterol-lowering ETC-1002. The company's approach is based on the official End-of-Phase 2 Meeting Minutes it received from the FDA.
    • The company plans to conduct multiple Phase 3 trials that will separately assess patients with statin intolerance and those who are inadequately treated despite maximally tolerated statin therapy. The design of the trials should be finalized in H1 2016 and will include long-term safety studies for patients on the maximum dose of statins. The length of the studies is the big question. An NDA filing could be 2018 or later, depending on the design of the trials.
    • The FDA has encouraged the company to promptly initiate a cardiovascular outcomes study which would be well underway at the time of an NDA filing but would need to be completed before regulatory approval if there are concerns over ETC-1002's benefit/risk assessment. Esperion intends to start the trial by the end of the year. If final results are required for the NDA, its filing would be pushed back another couple of years.
    • ETC-1002 inhibits an enzyme called ACL (ATP citrate lyase), which plays a key role in cholesterol synthesis in the liver.
    | Sep. 29, 2015, 9:08 AM | 12 Comments
Company Description
Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers.... More
Sector: Healthcare
Industry: Biotechnology
Country: United States